|10th June 2020||Enterprise Associates 12, Limited Partnership New||1,482,809||Other acquisition or disposition||$0.00|
|9th December 2019||Enterprise Associates 12, Limited Partnership New||400,000||Grant/award etc.||$6.25||$2,500,000.00|
|27th November 2019||Enterprise Associates 12, Limited Partnership New||1,166,755||Open or private sale||$2.52||$2,941,739.38|
|26th November 2019||Enterprise Associates 12, Limited Partnership New||117,164||Open or private sale||$2.45||$287,133.81|
|4th February 2019||Geoffrey S. Gilmartin||9,189||Open or private sale||$2.99||$27,479.70|
|4th February 2019||Po Shun Lee||9,931||Open or private sale||$2.99||$29,699.65|
|4th February 2019||Meenu Chhabra||16,478||Open or private sale||$2.99||$49,305.47|
|4th February 2019||Benito Munoz||9,514||Open or private sale||$2.99||$28,453.52|
|1st February 2019||Meenu Chhabra||46,875||Exercise of derivative||$0.00|
|1st February 2019||Benito Munoz||24,953||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases.